NGeneBio

Activity

2023-02-23

[Webinar] Introduction of NGS Panels and Software in Spanish 2023

On February 23, 2023, NGeneBio hosted an online webinar conducted in Spanish. The webinar served as a significant platform for introducing NGeneBio's NGS panels and disease genomics analysis software in Spanish. Its primary objective was to share information regarding innovative precision diagnostic technologies and genetic testing services. NGeneBio remains committed to providing educational resources in multiple languages to enhance the capabilities of its partners.

2023-02-09

[Conference/Exhibition] NGeneBio at MEDLAB 2023

NGeneBio participated in MEDLAB 2023, the largest medical equipment exhibition in the Middle East region, held at the Dubai World Trade Center from February 6 to February 9, 2023. At this exhibition, NGeneBio showcased the outstanding performance and market competitiveness of a wide range of precision diagnostic products, including HEMEaccuTest™ for blood cancer, ONCOaccuPanel™ for solid cancer, BRCAaccuTest™PLUS for breast and ovarian cancer, HLAaccuTest™ All for tissue compatibility antigens, MTBaccuPanel™ for tuberculosis, and NGeneAnaySys™ for disease genomics analysis software. Furthermore, NGeneBio conducted partnership meetings to fortify its presence in the NGS market in the Middle East and Africa, with the goal of expanding its global network. Leveraging its differentiated technology, NGeneBio is poised to lead the Middle East and Africa markets while also extending its reach into Europe and the Americas, thereby creating new business opportunities. For more detailed information about MEDLAB 2023, please visit www.medlabme.com

2022-12-06

[Conference/Exhibition] NGeneBio at the Korean Society of Diagnostic Genetics Symposium 2022

NGeneBio is excited to announce its participation in the Korean Society of Diagnostic Genetics Symposium, scheduled for December 7, 2022. The symposium will delve into various topics related to trends in circulating tumor nucleic acid (ctDNA) analysis technology, relevant issues, and the ethical, legal, and social implications (ELSI) of utilizing genomic data, which are actively applied in clinical practice. During this event, NGeneBio will unveil plans for the commercialization and technological collaboration for 'Minimal Residual Disease (MRD) Testing,' expanding its NGS precision diagnostic testing platform to encompass processes from diagnosis to monitoring for leukemia patients following diagnosis and treatment. NGeneBio aims to launch products that will facilitate this process within the year. We appreciate your interest in NGeneBio's endeavors!

2022-11-17

[Conference/Exhibition] NGeneBio at MEDICA 2022 (International Medical Equipment and Medical Technology Exhibition)

NGeneBio proudly participated in MEDICA 2022, the world's largest medical equipment exhibition, which took place in Dusseldorf, Germany from November 14 to November 17, 2022. At this exhibition, NGeneBio showcased an extensive range of precision diagnostic products, including the solid cancer precision diagnostic product ONCOaccuPanel™ and SOLIDaccuTest™. Additionally, they presented the blood cancer precision diagnostic product HEMEaccuTest™, tissue compatibility antigen precision diagnostic product HLAaccuTest™, precision diagnostic products for breast cancer and ovarian cancer, known as BRCAaccuTest™, tuberculosis precision diagnostic product MTBaccuPanel™, and cutting-edge disease genomics analysis software. Furthermore, in their quest to expand their footprint in the European NGS-based precision diagnostic service market, NGeneBio actively engaged in discussions about sales strategies and partnerships in response to the evolving market landscape. This strategic focus, particularly in Europe, centers on NGS clinical testing services and collaboration with sales representatives in key European regions and distributors. Their ambitious plans aim to extend their presence in the European and North African markets. * For detailed information about MEDICA 2022, please visit www.medica-tradefair.com

2022-11-04

[Conference/Exhibition] NGeneBio at the Korean Society of Pathology Autumn Conference 2022

NGeneBio exhibited at the Korean Society of Pathology Autumn Conference, held at The-K Seoul Hotel's Gaya Hall from November 2 to November 4, 2022. During this autumn conference, NGeneBio showcased its solid cancer precision diagnostic product, ONCOaccuPanel™, which has been commercialized following technology transfer from the Asan Medical Center. The company is now expanding its presence in both domestic and international markets. This event provided a valuable opportunity for NGeneBio to emphasize its innovative technologies and product strengths, thereby enhancing brand awareness. Building on this foundation, NGeneBio aims to further expand the adoption of NGS-based precision diagnostic products in medical institutions.

2022-10-28

[Conference/Exhibition] NGeneBio at the International Conference of the Korean Society of Clinical Laboratory Science (LMCE 2022)

NGeneBio attended the International Conference of the Korean Society of Clinical Laboratory Science (LMCE 2022), which took place at the Seoul Swiss Grand Hotel Convention Center from October 26 to October 28, 2022. During this academic conference, we introduced a range of precision diagnostic products, with a particular focus on our Next-Generation Sequencing (NGS) technology-based product, HLAaccuTest™. Additionally, we highlighted our tuberculosis diagnostic product, MTBaccuPanel™, as well as precision diagnostic products for breast cancer and ovarian cancer known as BRCAaccuTest™. We also presented our precision diagnostic test for blood-related cancers, called HEMEaccuTest™. Through our participation in this conference, NGeneBio solidified its position as a leading company in NGS precision diagnostics, showcasing a variety of precision diagnostic products based on Next-Generation Sequencing. We are committed to continually addressing unmet needs in the medical field and playing a pivotal role in the growth of the diagnostic medical device industry.

2023-09-14

NGeneBio Applies for U.S. Patent for Early Diagnosis Technology for Alzheimer's Disease

- Early diagnosis technology detecting Alzheimer's disease -related microRNAs in blood - Pursuing commercialization of Alzheimer's disease early diagnosis products and testing services in the United States On Sep 14th, NGeneBio, a company specializing in Next-Generation Sequencing (NGS)-based genomic analysis, announced that it has completed the US patent application for technology related to the diagnosis and monitoring of neurodegenerative brain diseases based on fluid analysis. The technology covered in this patent application allows for the diagnosis of dementia patients, including Alzheimer's disease, without the need for cerebrospinal fluid collection, unlike traditional diagnostic methods. It detects specific microRNAs (miRNAs) that uniquely increase in dementia patients. When the target biomarkers are detected, a fluorescent probe is used to quickly and accurately diagnose degenerative brain diseases, including Alzheimer's disease, in patients without discomfort. NGeneBio applied for this patent to gain a foothold in the US Alzheimer's disease market, which is valued at approximately 2 trillion won. They plan to develop products that combine the previously patented biomarkers for Parkinson's disease dementia and Lewy body dementia, applying algorithms for the classification and early diagnosis of various types of dementia using AI. In addition to product development, NGeneBio plans to set up Laboratory Developed Test (LDT) services in the CLIA lab (Clinical Laboratory Improvement Amendments Lab) they are in the process of acquiring. This will enable the commercialization of dementia early diagnosis tests alongside NGS-based precision cancer diagnostics in the US market. CEO of NGeneBio Choi Dae-chul stated, "We will continue to commercialize core technologies such as early diagnosis of dementia, which is a representative disease in the aging population, companion diagnostics for predicting the efficacy of anticancer drugs and treatment outcomes, and liquid biopsy-based prognostic diagnosis." He further added, "Through our ongoing acquisition of a US-based CLIA lab and NGeneBioAI, our US subsidiary, we will actively target the rapidly growing data-driven AI diagnostics market in the US." It is worth noting that NGeneBio previously signed an agreement in May to receive technology related to the diagnosis and monitoring of neurodegenerative brain diseases, including Alzheimer's disease, from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and the Industry-Academia Cooperation Foundation of Konyang University. US Alzheimer's Market Size: Approximately $1.6 billion in 2020 / Source: ResearchAndMarket Global Alzheimer's Market Size: Approximately $6.3 billion in 2020, with an annual growth rate of 6.5% / Source: MARC

2023-08-18

NGeneBio Co., Ltd. enters into a strategic alliance with MGI, a global NGS equipment company

Combining MGI's new NGS sequencing equipment with NGeneBio's cancer precision diagnosis productHand in hand to preoccupy the Asian region... Expansion of global distribution in the future Seoul, South Korean, 18 August, 2023 - NGeneBio (354200, CEO Choi Chul Choi), a company specializing in next-generation sequencing-based precision diagnosis platform, announced on the 18th that it had signed a business agreement with MGI, the largest NGS company in China and a global NGS equipment manufacturer. Founded in 2016, MGI is a leading producer of clinical high-throughput gene sequencers with over 2,800 employees, providing products and services in more than 90 countries and regions around the world, and serving more than 2,400 customers. In addition, as a company committed to building core tools and technology to lead life science, it has grown to become one of the two companies in the world that can independently develop and mass-produce low-, medium- and high-throughput clinical gene sequencers from GB to TB in about 7 years since its establishment. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation that can be applied to precision medicine, precision agriculture, precision healthcare and other relevant industries. Through this business agreement, the two sides will ▲apply NGeneBio’s NGS cancer precision diagnosis product to MGI’s NGS platform DNBSEQ-G99 sequencer , ▲joint local cooperation in Asia (Singapore, Thailand, Malaysia, Taiwan, Philippines, Indonesia, Vietnam, China, etc.) They plan to strengthen their competitiveness in the precision medical field by promoting commercialization, ▲joint marketing and ▲global distribution cooperation, and ▲promoting joint business development such as equipment and NGS diagnostic product package production.

2023-07-03

NGeneBio‘s Machine Learning Model for Genetic Variant Interpretation Published in "Nature Journal"

Improving the accuracy of NGS-based precision diagnostic results and securing product competitiveness.NGeneBio announced on last July 3rd, has published their research on gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants in the renowned scientific journal "Scientific Reports" by Nature. This research paper is about compared to the disease-specific approach, gene-specific supervised machine learning is even more specific as it builds pathogenicity predictors using variants from only a particular disease gene, e.g., BRCA1 or BRCA2. This method has the potential to perform best due to its highest specificity. Currently, the determination of the pathogenicity of genetic variants relies on information recorded in public databases, which only contain information on a small fraction of frequently occurring variants. NGeneBio has stated that the main focus of their research is to use machine learning algorithms to assess the pathogenicity of rare variants for which there is insufficient genetic information in these public databases. In this collaborative study between NGeneBio's research team and Professor Kyu-Baek Hwang's team from Soongsil University, they further investigated the advantages of “gene-specific” machine learning compared to “disease-specific” machine learning. We used 1068 rare (gnomAD minor allele frequency (MAF) < 0.005) missense variants of 28 genes associated with hereditary cancers for our investigation. Popular machine learning classifiers were employed: regularized logistic regression, extreme gradient boosting, random forests, support vector machines, and deep neural networks. As features, we used MAFs from multiple populations, functional prediction and conservation scores, and positions of variants. Despite the difficulty in interpreting the association between a specific variant and breast cancer due to insufficient data during the examination of rare genetic variants, they demonstrated the effective interpretation of rare gene mutations using machine learning even with a limited dataset. The most significant achievement was the improvement in prediction and analysis accuracy compared to other approaches by applying it to the prediction of pathogenic mutations in the BRCA1/2 genes associated with breast cancer.NGeneBio plans to apply these research findings in their breast cancer precision diagnostics product, BRCAaccuTest™PLUS. The accuracy of diagnostic results will be enhanced for breast cancer patients who were previously challenging to determine or diagnose as pathogenic due to lacked sufficient information. Currently, BRCAaccuTest is approved by the MFDS in Korea, being used in more than 10 major domestic hospital including Seoul National University Hospital and Seoul St. Mary's Hospital, as well as overseas medical institutions, such as in Singapore. It is expected that enhancing its competitiveness both domestically and internationally.Kwang-Joong Kim, the Head of NGeneBio R&D said that "By using gene-specific machine learning, we have been able to identify variants with inaccurate interpretations and clearly distinguish between clinically significant and non-significant variants. This has led to improved accuracy in NGS-based precision diagnostic results." He further added, "We will expand the application of this approach to all gene panel analyses based on NGS, enabling accurate diagnosis of challenging disease-associated genetic variants." Gene-specific machine learning for pathogenicity prediction of rare BRCA1 and BRCA2 missense variants | Scientific Reports (nature.com)

2023-02-02

NGeneBio launched NGS based breast cancer diagnostic service in Thailand

Launched NGS based breast cancer diagnostic service in a newly installed inspection laboratory of a Thai consignment inspection agency, MP Group. Expand precision diagnosis service and dominate the new market NGeneBio Co.,Ltd expands NGS based breast cancer diagnostic to Thailand with MP Group. The MP Group is Thailand's leading consignment inspection agency and distributor specializing in medical devices. They held a grand opening event to launch its first NGS service on last January. Using NGeneBio’s NGS-based precision diagnosis platform its provide to hospitals, government-affiliated medical institutions, health centers and the general public. Using NGeneBio’s BRCAaccuTest™PLUS test to identify the BRCA gene which is related to breast cancer and ovarian cancer. The BRCA test service provides -▲analyzes breast BRCA 1/2 gene mutation screening, ▲ an individual's innate breast cancer, ovarian cancer risk, ▲ family history to identify genetic characteristics, ▲and generates personalized gene reports. NGeneBio representatives also attended and presented the necessity of NGS precision diagnosis and introduced steady seller products . "Thailand has the largest medical device market among ASEAN countries due to the government's active support and investment in healthcare," said Choi Dae-chul of NGeneBio . "As we have been asked to cooperate in research on genome projects, we will make efforts to expand the Thai market and lead the NGS precision diagnosis market in Southeast Asia." "BRCAaccuTest PLUS is certified by FDA Thailand, It can be used not only as a diagnostic test for breast cancer target treatment but also as a test for mutation screening of BRCA1/2 genes," Rittichai Srivijarn of MP Group Chairman said. “Based on a friendly relationship with NGeneBio, we plans to expand the BRCA service as well as massively increase the number of joint projects.”

2022-11-25

NGeneBio entered into a supply contract with NUPCO in Saudi Arabia for its blood cancer NGS panel

25, November 2022, Precision diagnostics platform provider NGeneBio announced that it has inked a deal with NUPCO(National Unified Procurement Company) to supply its NGS panel for hematologic Malignancies, HEMEaccuTest™. According to the contract, NGeneBio will deliver kits based on a separate confirmed purchase order at the contract unit price for two years from the first quarter of 2023. NUPCO was established in 2009 by the government of Saudi Arabia. NUPCO has been centralizing procurement, warehousing, distribution, and re-exporting of pharmaceuticals, medical equipment and supplies for the benefit of all public hospitals and healthcare facilities. NGeneBio participated in the tender for blood cancer precision diagnosis products ordered by the Saudi government through a local distributor and will deliver about 4,000 blood cancer NGS panel kits, HEMEaccuTest™ to NUPCO through a local distributor. The products are currently being evaluated at Saudi hospitals, and blood cancer precision diagnosis tests will be conducted at Saudi hospitals as early as next year with NGeneBio's products supplied through NUPCO. NGeneBio's blood cancer precision diagnosis product, HEMEaccuTest™, is Asia's first CE-IVD certified blood cancer NGS panel in 2018. HEMEaccuTest™ was developed to detect blood cancer-related DNA and RNA, respectively. DNA test products can detect about 100 genes at once, and RNA test products can detect about 50 genes at once. In particular, It is an important determinant of the supply selection that NGeneBio’s panel is provided with analysis software NGeneAnySys, which can analyze major mutations that cause blood cancer and provides personalized prescriptions.

2022-06-15

NGeneBio, Genoks Health Service Inc sign MOU for NGS test collaboration

Precision diagnostics platform provider NGeneBio announced that it has inked a memorandum of understanding(MOU) with Turkish firm Genoks Health Service for the NGS test collaboration.Through the partnership, NGeneBio will supply its cancer precision diagnostics NGS panels, data analysis software, and nucleic acid extraction systems to Genoks. Genoks, having an R&D laboratory and carrying out more than 80,000 NGS tests, will conduct NGS tests with NGeneBio’s products for samples collected from Turkey, Iran, Azerbaijan, and Cyprus. NGeneBio expects it can expand its market presence to both Middle East and Western Asia through the partnership.Genoks is a Turkey-based company leading NGS test service market and started to routinely use the NIPT test based on NGS technology for the first time in Turkey. NGeneBio is a South Korea-based company that was founded in 2015 and has launched clinical NGS kits and analysis/interpretation software covering cancer diagnostics area: BRCA 1&2 (firstly approved by Ministry of Food and Drug Safety in South Korea, and CE-IVD marked), solid tumor (CE-IVD), hematological malignancies (CE-IVD), comprehensive oncology (CE-IVD), HLA-Typing (CE-IVD), and Tuberculosis detection (CE-IVD) products.

Promotion